HSD17B1
HSD17B1 (hydroxysteroid 17-beta dehydrogenase 1, also known as EDH17B2, EDHB17, HSD17 and SDR28C1) is a short-chain dehydrogenase/reductase that favours the reduction of oestrogens and androgens. It converts estrone to the more potent oestrogen 17beta-estradiol. Browse Assay Genie's current range of HSD17B1 research reagents below, or read on for the biology behind the target.
HSD17B1 is a steroid-metabolising oxidoreductase that favours the reduction of oestrogens and androgens. Its best-described reaction is the conversion of estrone (E1) to 17beta-estradiol (E2), a considerably more potent oestrogen. It also has 20-alpha-HSD activity. UniProt notes a preference for NADH as cofactor, while the NCBI Gene summary describes the final step of oestrogen activation as using NADPH. Through this activity it has a dual role in oestrogen activation and androgen inactivation, and it contributes to the E2 concentration gradient between serum and peripheral tissues.
The protein belongs to the short-chain dehydrogenase/reductase (SDR) family and is a member of the 17beta-hydroxysteroid dehydrogenase group. It has an N-terminal short-chain dehydrogenase domain that carries the cofactor binding site, and a narrow, hydrophobic C-terminal domain that forms the steroid substrate binding site. UniProt lists its subcellular location as the cytoplasm. According to NCBI, the HSD17B1 gene is expressed mainly in the placenta and ovarian granulosa cells, and to a lesser extent in the endometrium, adipose tissue and prostate. A pseudogene has been identified, and alternative splicing gives rise to multiple transcript variants.
Polymorphisms in the HSD17B1 gene have been linked to breast and prostate cancer, which makes the enzyme a point of interest in hormone-dependent disease research. Older names and symbols for the gene include hydroxysteroid (17-beta) dehydrogenase 1, MGC138140 and EDH17B2. Mouse and rat each have an orthologous gene, Hsd17b1, which supports comparative work on steroid metabolism.
HSD17B1 catalyses the conversion of estrone to the more potent 17beta-estradiol, so it is a key enzyme for studying oestrogen activation.
Polymorphisms in the HSD17B1 gene have been linked to breast and prostate cancer, which makes it relevant to hormone-driven tumour research.
The enzyme has a dual function in oestrogen activation and androgen inactivation, which makes it useful for studying how steroid balance is regulated.
Expression is highest in placenta and ovarian granulosa cells, with lower levels in endometrium, adipose tissue and prostate.
HSD17B1 favours the reduction of oestrogens and androgens. It converts estrone to the more potent oestrogen 17beta-estradiol and also has 20-alpha-HSD activity. It has a dual role in oestrogen activation and androgen inactivation, and it helps set the E2 gradient between serum and peripheral tissues.
HSD17B1 is also called 17-beta-hydroxysteroid dehydrogenase type 1, hydroxysteroid (17-beta) dehydrogenase 1, HSD17, SDR28C1, EDHB17, EDH17B2 and MGC138140. According to NCBI, alternative splicing produces multiple transcript variants, and a pseudogene of the gene has been identified.
Mouse and rat both carry an ortholog named Hsd17b1. In humans, polymorphisms in the gene have been linked to breast and prostate cancer. Check the datasheet of any product for its validated reactivity.
Other hydroxysteroid dehydrogenases from the short-chain dehydrogenase/reductase superfamily that act in steroid metabolism.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P14061; product specifications from Assay Genie datasheets.